DiscoverTalking Precision MedicineThe Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35
The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

Update: 2024-04-12
Share

Description

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.


Episode 35 links:






Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

Genialis